Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy. - Georgy, Josh Thomas; Regi, Soumya Susan; Georgy, Rosh Varghese; Sasidharan, Balu Krishna; Joel, Anjana; Philip, Deepa Susan Joy; John, Ajoy Oommen; Thumaty, Divya Bala; Marimuthu, Praveen Kumar; Jambunathan, Prashant; Harikrishna, Kovilapu; Thomas, Zachariah; et al. (Scientific Reports, 2025)